Publication Date
8-21-2023
Journal
Chemical Research in Toxicology
DOI
10.1021/acs.chemrestox.3c00164
PMID
37531179
PMCID
PMC10445284
PubMedCentral® Posted Date
8-2-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Mice, Humans, Animals, Cytochrome P-450 CYP3A, Chromatography, Liquid, Tyrosine Kinase Inhibitors, Tandem Mass Spectrometry, Protein Kinase Inhibitors, Cytochrome P-450 CYP3A Inhibitors, Microsomes, Liver, Metabolomics, Chemical and Drug Induced Liver Injury, Glutathione
Abstract
Pexidartinib (PEX, TURALIO), a selective and potent inhibitor of the macrophage colony-stimulating factor-1 receptor, has been approved for the treatment of tenosynovial giant cell tumor. However, frequent and severe adverse effects have been reported in the clinic, resulting in a boxed warning on PEX for its risk of liver injury. The mechanisms underlying PEX-related hepatotoxicity, particularly metabolism-related toxicity, remain unknown. In the current study, the metabolic activation of PEX was investigated in human/mouse liver microsomes (HLM/MLM) and primary human hepatocytes (PHH) using glutathione (GSH) and methoxyamine (NH2OMe) as trapping reagents. A total of 11 PEX-GSH and 7 PEX-NH2OMe adducts were identified in HLM/MLM using an LC–MS-based metabolomics approach. Additionally, 4 PEX-GSH adducts were detected in the PHH. CYP3A4 and CYP3A5 were identified as the primary enzymes responsible for the formation of these adducts using recombinant human P450s and CYP3A chemical inhibitor ketoconazole. Overall, our studies suggested that PEX metabolism can produce reactive metabolites mediated by CYP3A, and the association of the reactive metabolites with PEX hepatotoxicity needs to be further studied.
Graphical Abstract
Included in
Biochemical Phenomena, Metabolism, and Nutrition Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Medical Cell Biology Commons, Medical Genetics Commons, Medical Specialties Commons
Comments
Associated Data